It’s been almost a year since Capital One’s $35.3 billion deal to acquire Discover shocked the credit card industry. The merger is on track for approval at shareholder meetings scheduled for ...

NIPPON Steel and United States Steel claimed former President Joe Biden unfairly prejudged their US$14.1 billion merger and gave the companies no chance for feedback on a “sham” national security ...

TOKYO (Reuters) -Nissan looks set to step back from merger talks with rival Honda ... Honda is Japan's second-largest car maker behind Toyota, and Nissan is the third-largest.

The Seoul High Court upheld the lower court’s ruling dismissing all the charges from a case involving a 2015 merger that prosecutors said was designed to cement his control of the tech giant.

The Seoul High Court upheld the lower court's ruling dismissing all the charges from a case involving a 2015 merger that prosecutors said was designed to cement Lee's control of the tech giant. The ...

Samsung Chief Jay Y. Lee Found Not Guilty in Merger Case By Joyce Lee and Hyunjoo Jin SEOUL (Reuters) - Samsung Electronics Chairman Jay Y. Lee was found not guilty of accounting fraud and stock ...

Honda Motor Co and Nissan Motor Co say they will unveil the details of their merger plan in mid-February, having originally announced they would do so by the end of January. Honda and Nissan, Japan's ...

But when that car has been driven by a two-time Masters champion? That’ll certainly drive the price up. Last week, CBS’ lead golf play-by-play announcer Jim Nantz was able to add a rare ...

The Seoul High Court upheld the lower court's ruling dismissing all the charges from a case involving a 2015 merger that prosecutors said was designed to cement Lee's control of the tech giant.

Zwyer, NLS's CEO & Executive Board Member, stated: “Receiving approval from Kadimastem's shareholders is a significant step forward in the merger process". NLS is also planning to convene a ...

ZURICH and NESS ZIONA, Israel, Jan. 31, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...